Short Interest of The Day: AC Immune SA (NASDAQ:ACIU) Can’t Be More Risky. Short Interest Increased

November 23, 2016 - By Marie Mckinney   ·   0 Comments

Short Interest of The Day: AC Immune SA (NASDAQ:ACIU) Can't Be More Risky. Short Interest Increased

The stock of AC Immune SA (NASDAQ:ACIU) registered an increase of 1245.83% in short interest. ACIU’s total short interest was 96,900 shares in November as published by FINRA. Its up 1245.83% from 7,200 shares, reported previously. With 132,200 shares average volume, it will take short sellers 1 days to cover their ACIU’s short positions. The short interest to AC Immune SA’s float is 0.52%. About 32,682 shares traded hands. AC Immune Ltd (NASDAQ:ACIU) has risen 6.00% since October 24, 2016 and is uptrending. It has outperformed by 0.67% the S&P500.

AC Immune Ltd is a Switzerland-based firm engaged in the medical biotechnology sector. The company has a market cap of $644.96 million. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. It has a 30.53 P/E ratio.

More important recent AC Immune Ltd (NASDAQ:ACIU) news were published by: Reuters.com which released: “BRIEF-Ac Immune reports Q3 results” on November 26, 2015, also Globenewswire.com published article titled: “AC Immune SA announces results of annual general meeting”, Businesswire.com published: “Down Syndrome Pipeline Review, H1 2016 Featuring AC Immune, Aelis Farma S.A.S …” on March 23, 2016. More interesting news about AC Immune Ltd (NASDAQ:ACIU) was released by: Bioworld.com and their article: “AC Immune’s series E adds $44M as European biotech’s private equity reaches $725M” with publication date: May 10, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marie Mckinney


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>